Journal News

From the journals: JLR

Lydia Smith
March 7, 2024

What activates T cells in psoriasis? Lysosomal acid lipase in liver disease. A controlled diet targets heart disease risk. Read about papers on these topics recently published in the Journal of Lipid Research.

 

What activates T cells in psoriasis?

Psoriasis is a disease commonly identified by lesions; skin cells proliferate, white blood cells infiltrate and lipid metabolism is altered in the skin. In the past, researchers have shown that n-3 polyunsaturated fatty acids, or PUFAs, may suppress this inflammation, thus slowing disease progression. A recent study in the Journal of Lipid Research by Sophie Morin and a team at Laval University aimed to identify the role of n-3 PUFAs — specifically eicosapentaenoic acid, or EPA — in T cell activation and polarization in psoriasis.

Characteristically, psoriasis causes an increase in IL-17A, an inflammatory cytokine produced primarily by the Th17 subset of helper T cells, commonly known as CD4+ T cells.  Morin’s team found that, in the presence of EPA, IL-17A production is reduced, and FOXP3+ regulatory T cell production increases. They determined that EPA inhibition of STAT3, a signaling protein on the cell surface that activates and polarizes Th17 cells, prevented polarization to a Th17 proinflammatory phenotype. This inhibition was specific to STAT3; EPA did not reduce polarization to a proinflammatory Th1 phenotype via STAT1. 

The researchers used a 3D model of psoriatic skin to show that EPA reduced proliferation of skin cells, transduction protein phosphorylation and transcription activation. They also noted that the NF-κB pathway was altered, which led to increased concentrations of Fas, a death receptor located on the cell surface, causing increased cell death.

The researchers deduced that EPA and other n-3 PUFAs act as antiinflammatory mediators of psoriasis by simultaneously producing regulatory T cells and reducing proinflammatory T cell phenotypes, as well as altering major signaling pathways promoting psoriasis symptom reduction. 

 

Lysosomal acid lipase in liver disease

Lysosomal acid lipase, LAL, plays a key role in metabolism and is the only enzyme known to degrade both cholesteryl esters and triglycerides at an acidic pH.  Dysfunction of LAL causes a rare, autosomal recessive genetic disorder known as LAL deficiency, or LAL-D, and researchers have found that reduced LAL activity contributes to the progression of nonalcoholic fatty liver disease, or NAFLD.  In a recent paper published in the Journal of Lipid Research, Ivan Bradić at the Medical University of Graz and collaborators aimed to learn more about liver-related pathologies of LAL through proteomic profiling. 

In mice genetically altered to systemically lack the LAL gene, the researchers noted significant alterations in the proteome compared to their wild-type counterparts and to mice genetically altered to lack hepatocyte-specific LAL.  Results indicated substantial liver remodeling, upregulation of glycolysis-associated proteins, increased cholesterol metabolism and hydrolase concentration, and decreased production of proteins associated with lipid and fatty acid metabolism. 

Evidence of macrophage abundance, immunity, autophagy, apoptosis and immune processes involving myeloid cells increased in the mice lacking the LAL gene, suggesting higher levels of inflammation. This suggests metabolic alteration, inflammation and restructuring of the liver in LAL-D or NAFLD, which is most strongly modeled in models systematically lacking the LAL gene. These findings will aid in further characterization and potential therapeutic development for NAFLD. 

 

Controlled diet targets heart disease risk

Saturated fatty acids, or SFAs, are found in foods such as full-fat dairy, red meat and poultry. Scientists have linked SFAs to production of low-density lipoprotein cholesterol, or LDL-C, which increases the risk of cardiovascular disease, or CVD.  In the past, researchers have found that lipoprotein(a), or Lp(a), is similar to LDL-C, but poses an independent risk for CVD. While these factors are true for most ethnicities, individuals of African American descent experience a higher risk. For this reason, Hayley G. Law at the University of California, Davis and her collaborators aimed to identify an SFA-dependent relationship between Lp(a) and CVD risk in African American populations. They wrote about their work in a study recently published in the Journal of Lipid Research.

Study participants ate two diets sequentially, each for five weeks. The first was similar to the average American diet, or AAD, while the second contained a decreased amount of SFA.  This diet resembles the dietary approaches to stop hypertension, or DASH, diet, which was supplemented with carbohydrates.  As expected, switching from an AAD diet to a DASH diet resulted in a significant reduction in cholesterol, specifically LDL-C. Lp(a) levels were increased upon switching to the DASH diet, which the researchers speculate may be due to the carbohydrate supplementation.  In the future, they may examine this relationship more deeply, determine the specific mechanisms that cause Lp(a) increases with SFA reduction and identify appropriate nutritional replacements.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Lydia Smith

Lydia Smith has a B.S. in molecular cell biology and a minor in chemistry, which she received from California State University, Long Beach. She is continuing on to receive her Ph.D. in microbiology and immunology at the University of Utah and is a volunteer contributor for ASBMB Today. 

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
Feature

Using 'nature’s mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
News

Cracking cancer’s code through functional connections

July 2, 2025

A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.